We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+4.99%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$110B
AUM Growth
+$11.3B
(+11%)
Cap. Flow
+$8.89B
Cap. Flow
% of AUM
8.09%
Top 10 Holdings %
Top 10 Hldgs %
35.27%
Holding
3,643
New
809
Increased
972
Reduced
1,047
Closed
744
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$3.35B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$2.85B |
| 3 |
Eli Lilly
LLY
|
+$999M |
| 4 |
Coca-Cola
KO
|
+$685M |
| 5 |
Broadcom
AVGO
|
+$616M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.38B |
| 2 |
Apple
AAPL
|
+$1.12B |
| 3 |
Netflix
NFLX
|
+$678M |
| 4 |
Boston Scientific
BSX
|
+$671M |
| 5 |
Cencora
COR
|
+$627M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Consumer Discretionary | 12.77% |
| 3 | Healthcare | 10.45% |
| 4 | Financials | 7.74% |
| 5 | Communication Services | 5.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
Howard Hughes
HHH
$4B
| $2.12M | ﹤0.01% |
26,526
+21,727
| +453% | +$1.8M |
|
1527
Design Therapeutics
DSGN
$915M
| $2.12M | ﹤0.01% |
+225,528
| New | +$1.77M |
|
1528
Popular Inc
BPOP
$11.2B
| $2.11M | ﹤0.01% |
16,982
+1,199
| +8% | +$142K |
|
1529
Everspin Technologies
MRAM
$400M
| $2.11M | ﹤0.01% |
227,049
-55,689
| -20% | -$530K |
|
1530
NewMarket
NEU
$8.43B
| $2.1M | ﹤0.01% |
3,062
+2,758
| +907% | +$2.11M |
|
1531
Cabaletta Bio
CABA
$455M
| $2.1M | ﹤0.01% |
959,076
-366,967
| -28% | -$909K |
|
|
ASIC
1532
Ategrity Specialty Insurance
ASIC
$1.2B
| $2.1M | ﹤0.01% |
99,894
-6,701
| -6% | -$127K |
|
1533
Walker & Dunlop
WD
$1.48B
| $2.09M | ﹤0.01% |
+34,809
| New | +$2.47M |
|
|
BWIN
1534
Baldwin Insurance Group
BWIN
$2.88B
| $2.09M | ﹤0.01% |
+87,008
| New | +$2.22M |
|
1535
American Coastal Insurance
ACIC
$464M
| $2.09M | ﹤0.01% |
165,494
+57,443
| +53% | +$694K |
|
1536
Eos Energy Enterprises
EOSE
$1.54B
| $2.09M | ﹤0.01% |
182,167
+168,416
| +1,225% | +$2.42M |
|
1537
EVgo
EVGO
$503M
| $2.09M | ﹤0.01% |
717,203
-228,630
| -24% | -$831K |
|
1538
Apple Hospitality REIT
APLE
$3.68B
| $2.08M | ﹤0.01% |
175,884
+129,722
| +281% | +$1.52M |
|
1539
Kimbell Royalty Partners
KRP
$1.5B
| $2.08M | ﹤0.01% |
+176,612
| New | +$2.26M |
|
1540
Ovid Therapeutics
OVID
$482M
| $2.07M | ﹤0.01% |
1,271,487
+487,834
| +62% | +$751K |
|
1541
MacroGenics
MGNX
$249M
| $2.07M | ﹤0.01% |
1,284,563
+655,028
| +104% | +$1.03M |
|
|
CTNM
1542
Contineum Therapeutics
CTNM
$558M
| $2.07M | ﹤0.01% |
180,804
-12,687
| -7% | -$145K |
|
1543
AMN Healthcare
AMN
$1.28B
| $2.07M | ﹤0.01% |
131,042
-103,815
| -44% | -$1.85M |
|
1544
Acadia Realty Trust
AKR
$2.83B
| $2.06M | ﹤0.01% |
100,156
-170,564
| -63% | -$3.4M |
|
1545
Xcel Energy
XEL
$48.5B
| $2.06M | ﹤0.01% |
27,850
-758,102
| -96% | -$59.8M |
|
1546
Varex Imaging
VREX
$783M
| $2.06M | ﹤0.01% |
176,541
-4,400
| -2% | -$51.5K |
|
1547
Atlanta Braves Holdings Series B
BATRK
$3.27B
| $2.05M | ﹤0.01% |
51,999
+42,211
| +431% | +$1.67M |
|
1548
Meridian
MRBK
$236M
| $2.05M | ﹤0.01% |
116,572
+10,574
| +10% | +$165K |
|
1549
SPX Corp
SPXC
$10.9B
| $2.04M | ﹤0.01% |
+10,208
| New | +$2.08M |
|
1550
Cabot Corp
CBT
$4.49B
| $2.04M | ﹤0.01% |
+30,768
| New | +$2.05M |
|
Similar funds
Marshall Wace's Q4 2025 Portfolio in Review
As of Q4 2025, Marshall Wace held 3,643 positions worth $110B, up 11% from $98.6B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Marshall Wace deployed $8.89B of net new capital in Q4 2025, opening 809 new positions and adding to 972 existing holdings. Its largest new stake was Vanguard S&P 500 ETF: 4,580,704 shares worth $2.87B.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Microsoft, an estimated $1.38B trimmed.
- Marshall Wace's largest Q4 2025 buy was Vanguard S&P 500 ETF: 4,580,704 shares worth $2.87B.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q4 2025, an estimated $3.35B increase.
- Marshall Wace's biggest Q4 2025 reduction was Microsoft, cutting an estimated $1.38B.
- Marshall Wace fully exited Ares Management in Q4 2025, selling an estimated $146M.
- Marshall Wace's ten largest holdings make up 35% of its $110B portfolio in Q4 2025.
- Marshall Wace opened 809 new positions and closed 744 in Q4 2025.
- Marshall Wace's portfolio value rose 11% quarter-over-quarter to $110B.
Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.